학술논문
COVID‐19 vaccine acceptance and hesitancy in patients with immunobullous diseases: a cross‐sectional study of the International Pemphigus and Pemphigoid Foundation.
Document Type
Article
Source
Subject
*VACCINE hesitancy
*COVID-19 vaccines
*CROSS-sectional method
*COVID-19
*PEMPHIGUS
*BULLOUS pemphigoid
*
*
*
*
*
Language
ISSN
0007-0963
Abstract
Conscientious communications targeting patient concerns, such as information about risk-benefit ratios,4 are necessary to tackle COVID-19 vaccine hesitancy among patients with AIBDs, particularly in light of recent recommendations for booster immunizations (www.cdc.gov). Right panels: adjusted odds ratios determined by ordinal logistic regression for willingness (a) and logistic regression for hesitancy (b), comparing the rate of COVID-19 vaccination willingness/hesitancy between the different covariate levels. Dear Editor, Patients with autoimmune bullous diseases (AIBDs) have faced considerable challenges during the COVID-19 outbreak.1 SARS-CoV-2 vaccines became an important public health solution, but the pandemic raised awareness of vaccine hesitancy.2 We aimed to investigate the currently unknown general vaccination status among patients with AIBDs to better inform vaccine practices in this cohort of patients with potentially life-threatening inflammatory disorders. [Extracted from the article]